The phase III trial compared pembrolizumab with the investigator’s choice of chemotherapy as first-line treatment for patients with advanced NSCLC and PD-L1-tumor proportion score (TPS) ≥ 50% [6]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.